Procept BioRobotics Corp (PRCT)

NASD · Healthcare · Medical Devices · USA

Procept BioRobotics Corp is a small cap company (market value between $300 million and $2 billion) in the Medical Devices industry.

Procept BioRobotics is a surgical robotics company that makes and sells two robotic platforms for minimally invasive urologic procedures to treat benign prostatic hyperplasia. The systems use proprietary water-jet technology combined with imaging and automated robotics to remove prostate tissue. The company sells to hospitals, surgery centers and leasing companies across the United States and internationally.

From its FY2025 annual report (Form 10-K)

Intrinsic value, DCF valuation, financial health and value investing analysis for the Procept BioRobotics Corp stock.

Our verdict on PRCT

Overvalued: intrinsic value $14.11 per share, market price $23.78, margin of safety -68.5% (as of 2026-11-17).

A 1.6x revenue multiple, discounted for its losses, values the shares at $14.11; the price of $23.78 is 69% above that value.

ETFs with the most weight in PRCT

17 more funds hold it; the full list is part of the paid plan.

More on PRCT

Browse

Peers in Medical Devices

All 140 Medical Devices stocks

Cheaper than PRCT in Medical Devices

34 more in this industry show a wider margin of safety.

Is PRCT undervalued or overvalued?

PRCT is overvalued (as of the 2026-11-17 close). A 1.6x revenue multiple, discounted for its losses, values the shares at $14.11; the price of $23.78 is 69% above that value.

What is the intrinsic value of PRCT?

$14.11 per share (as of the 2026-11-17 close), against a market price of $23.78. That is a margin of safety of -68.5%. The value comes from the one valuation method that applies to this company, recomputed every night after the US close.